Sunday, 22 April 2018 - 7:46
  • it
  • de
  • en
  • fr

Samsung Bioepis

Biogen’s Imraldi, biosimilar to Humira, approved in Europe

Biogen has announced that the European Commission has approved Imraldi, a biosimilar to Humira. The drug has been co-developed by a Biogen-Samsung Bioepis joint venture. It has been approved for the treatment of rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis…

Samsung Bioepis announces important agreement with Takeda

Samsung Bioepis, part of South-Corea-based Samsung, today issued an important press release to announce it signed an agreement with Japan-based Takeda Pharmaceuticals to develop new drugs. Bioepis, founded in 2012, only focused on developing biosimilars up to now, and the…